All News
Filter News
Found 43 articles
-
International experts join Microba Life Sciences inaugural IBD Advisory Panel
6/28/2021
Precision microbiome science company, Microba Life Sciences, has appointed three respected key opinion leaders in Inflammatory Bowel Disease (IBD) to their IBD Advisory Panel to translate research into clinical outcomes for IBD sufferers.
-
Microba Life Sciences and Illumina partner to accelerate microbiome research
5/25/2021
Leaders in precision gut microbiome science Microba Life Sciences has united with Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies to advance understanding of the human gut microbiome in human health and disease.
-
Forensic DNA preservation method best for gut microbiome samples: Microba Life Sciences
5/7/2021
Microba Life Sciences, leaders in precision gut microbiome science, have demonstrated the superiority of their faecal sample preservation method against others, with a robust, peer-reviewed study published in ISME Communications.
-
Genetic Analysis Joins Microbiome Therapeutics Innovation Group
5/3/2021
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Norwegian molecular diagnostic company Genetic Analysis AS to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.
-
Microba Life Sciences study shows Microba Community Profiler outperforms competition
4/23/2021
Leaders in precision gut microbiome science, Microba Life Sciences have demonstrated how their proprietary Microba Community Profiler compares to other metagenomic profilers, with the study published in Frontiers in Microbiology.
-
Servatus Biopharmaceuticals Joins Microbiome Therapeutics Innovation Group
3/29/2021
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Australian Biotech company Servatus Biopharmaceuticals Ltd to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.
-
Microba Life Sciences appoints experienced executive Mark Capone to the Board
3/18/2021
Microba Life Sciences has appointed international executive, Mark Capone, as a Non-Executive Director of the Board, bringing with him more than 35 years of experience in the life sciences sector.
-
Microba Life Sciences partners with Unilever to target sleep through the gut microbiome
3/15/2021
The Centre for Disease Control and Prevention has declared insufficient sleep a 'public health problem', with more than one-third of American adults not getting enough sleep on a regular basis.
-
Microba Life Sciences Joins Microbiome Therapeutics Innovation Group
2/22/2021
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Microba Life Sciences to its coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products.
-
Microba co-founder and gut analysis expert to head microbiome research at QUT
2/28/2020
Co-founder of Brisbane-based gut analysis company Microba, Professor Gene Tyson, will head up a new field of microbiome-focused research at the Queensland University of Technology.
-
Psomagen-Macrogen Consortium Acquires All Patents and Data From US Company uBiome
1/2/2020
On January 2nd, the Psomagen-Macrogen Consortium announced the acquisition of all key assets of US company uBiome.
-
Microba founder next Southern Hemisphere VP of international society
12/23/2019
Co-founder of Brisbane-based gut analysis company Microba, Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).
-
Microba co-founders and Senior Bioinformatician named in 2019 Highly Cited Researchers list
11/20/2019
Gut microbiome analysis experts Microba had three of their researchers – including both co-founders – named in the 2019 Highly Cited Researchers list by the Web of Science Group released yesterday.
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
-
Brisbane’s Microba represented at international competition in Berlin
11/12/2019
Brisbane biotech Microba were chosen to participate in international pitching competition, the Falling Walls Venture in Berlin, based on their world-leading work in analysing gut bacteria.
-
Gut health testing biotech Microba wins 2019 Lord Mayor’s Innovation Award
10/18/2019
Brisbane-based world leaders in metagenomic testing, Microba, have won the 2019 Product Innovation Award at the Lord Mayor’s Awards Dinner tonight
-
Anixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board
10/10/2019
Anixa Biosciences, Inc. announced the appointment of Ian H. Frazer, MD, AC, FRS, FAA, to its Scientific Advisory Board.
-
Microba and Google Cloud use innovation and AI to level up gut microbiome testing
9/27/2019
CEO of gut health testing specialists Microba, Blake Wills, presented at the Google Cloud Summit in Sydney last week to share how working with global powerhouse Google Cloud allowed the startup to combine expert scientific knowledge with high-powered analytics and machine learning capabilities.
-
Gut health testing biotech Microba up for the 2019 Lord Mayor’s Innovation Award
9/16/2019
Brisbane-based world leaders in metagenomic testing, Microba, are among 56 finalists competing for a Lord Mayor’s Award in October this year, as a finalist in the product innovation category.
-
Brisbane-based Microba partners with UNSW Sydney’s Microbiome Research Centre to deliver world-class analysis
8/23/2019
Australia’s leading gut microbiome testing specialists Microba have partnered with the Microbiome Research Centre at UNSW to power new gut microbiome research to discover new links with disease states and potential therapeutics.